Acoltremon

Acoltremon

SCHEMBL619824

COc1ccc(NC(=O)C2CC(C)CCC2C(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 1.00
TRPV1 Q8NER1 2/20 0.57
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
HPGD P15428 2/20 0.47
POLB P06746 1/20 0.47
EPHX1 P07099 1/20 0.47
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
EPHX2 P34913 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acoltremon SCHEMBL29570327 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL29225639 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL2575067 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL23870506 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL3228667 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL23198293 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL14811473 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL17104729 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
Acoltremon SCHEMBL16227989 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1KMT2ANPC1
SCHEMBL2628780 0.88 TRPM8 (0.78) TRPM8TRPV1KMT2AHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12397518-B2 WS12-releasing contact lens COOPERVISION INTERNATIONAL LIMITED (GB) 2025-08-26 US claimed
WO-2025068299-A1 AEROSOL-GENERATING ARTICLE, DEVICE AND SYSTEM JT INTERNATIONAL SA (CH) 2025-04-03 WO claimed
CN-117099025-B WS12 releasing contact lens 库博光学国际有限公司 2025-03-11 CN claimed
EP-4288813-B1 WS12-RELEASING CONTACT LENS COOPERVISION INT LTD (GB) 2024-09-04 EP claimed
EP-4407354-A2 WS12-RELEASING CONTACT LENS CooperVision International Limited (GB) 2024-07-31 EP claimed
CN-118076340-A Ophthalmic pharmaceutical composition and use thereof 爱瑞制药公司 2024-05-24 CN claimed
CN-117752549-A Oral care compositions containing bioactive enzymes and uses thereof 北京心悦创造科技有限公司 2024-03-26 CN claimed
US-11934044-B2 WS12-releasing contact lens COOPERVISION INTERNATIONAL LIMITED (GB) 2024-03-19 US claimed
CN-117582380-A Oral care composition, application thereof and toothpaste 北京心悦创造科技有限公司 2024-02-23 CN claimed
US-20240036354-A1 WS12-RELEASING CONTACT LENS COOPERVISION INTERNATIONAL LIMITED (GB) 2024-02-01 US claimed
US-20140134113-A1 PHARMACEUTICAL COMPOSITIONS SYMRISE AG (DE) 2014-05-15 US claimed
EP-2730280-A1 A pharmaceutical composition comprising a menthane carboxylic acid amide Symrise AG (DE) 2014-05-14 EP claimed
WO-2013164706-A1 SMOKING ARTICLE MOUTHPIECE WITH COOLING AGENT INCLUSION COMPLEX PHILIP MORRIS PRODUCTS S.A. (CH) 2013-11-07 WO claimed
US-20130156885-A1 CHEWING GUM CONTAINING COMBINATIONS OF PHYSIOLOGICAL COOLING AGENTS WM. WRIGLEY JR. COMPANY 2013-06-20 US claimed
US-20110081303-A1 TEETH CLEANING COMPOUND CONTAINING MENTHOL WITH REDUCED BITTER SENSATION SYMRISE AG (DE) 2011-04-07 US claimed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US claimed
WO-2009027331-A2 TIPPING PAPER BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) 2009-03-05 WO claimed
WO-2008138162-A1 COMPOSITIONS AND THEIR USE GIVAUDAN SA (CH) 2008-11-20 WO claimed
US-20070233026-A1 Absorbent articles with feedback signal upon urination THE PROCTER & GAMBLE COMPANY 2007-10-04 US claimed
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods GENENTECH, INC. 2005-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods TSG101, TP53, BAX TRPM8 28/4885TRPV1 14/4885MEN1 3338/4885
US-20110081303-A1 TEETH CLEANING COMPOUND CONTAINING MENTHOL WITH REDUCED BITTER SENSATION TAS2R10, TAS2R30, TAS2R14 TRPM8 45/4885TRPV1 93/4885MEN1 2898/4885
US-20140134113-A1 PHARMACEUTICAL COMPOSITIONS CYP2C19, CYP3A7, CYP3A4 TRPM8 109/4885TRPV1 346/4885MEN1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.